September the 23rd, 2023 – The Croatian JGL Pharma Valley has presented a massive investment totalling 53 million euros. Owing to this, it will be able to expand its production capacities by 60%.
As Poslovni Dnevnik/Josipa Ban writes, the completion of an investment in the INTEGRA project was recently marked at the Croatian JGL Pharma Valley. A significant number of guests from the world of business and politics were presented with new laboratories for research, development and quality control, a pilot plant and a line for the sterile production of drops and sprays. Owing to all of the above, the Croatian JGL’s production capacities are set to increase by as much as 60 percent.
Everything from a restaurant to new museum displays
JGL’s brand new robotic logistics and distribution centre with 17,500 pallet spaces, located in Rijeka’s Kukuljanovo business zone, was also presented along with the rest. In addition to the above, as part of the INTEGRA project, additional facilities were constructed which will work to improve the working conditions of employees and guests in the Pharma Valley complex. There will be a brand new restaurant, new office spaces, a lecture hall, a multi-purpose meeting hall and a new display of the JGL Pharmacy Museum.
“At INTEGROM, we’re significantly increasing our technological equipment and capacities and creating the prerequisites for further advancement of our key brands on the global health market,” said Ivo Usmiani, chairman of the Board of Directors of JGL, a company that generated 190 million euros in revenue last year. In front of the gathered audience, where some of the top political leaders were sitting, Usmiani added that some particularly important decisions remain recorded in the life of every company, after which the present and the future take on a completely new dimension.
“At JGL, we’ve always known that we had the ability to grow, we dreamed of becoming an international pharmaceutical company that operates far beyond the borders of Croatia from a small local laboratory. Modestly, persistently and patiently, with a lot of passion and energy, we built what we now have, as well as a respected international position. Today, with our 150 brands, 300 products and 650 variations, we’re present in 60 markets around the globe. Exports make up 86 percent of our business income,” Usmiani pointed out.
Influenza, cold viruses, ophthalmology and dermatology
The increase in the Croatian JGL’s research and development capacities, as well as their integration with production and quality all in one location, will strengthen JGL’s position in the development and production of advanced, innovative products within three strategic therapeutic areas – flu and colds, ophthalmology and dermatology. This was explained the chief executive officer of JGL, Mislav Vučić. He added, however, that the key to success is the employees themselves. “I want to thank the team that diligently and expertly led this project, as well as the entire collective of JGL, Adrialab and Pablo, which consists of 1,241 individuals, who motivated and successfully realised our goals, aware that competition with global multinational companies requires excellence in everything we do,” stated Vučić.
The PM was impressed and warmly congratulated JGL
Prime Minister Andrej Plenković also made sure to congratulate the successfully completed project and pointed out that he is proud of what JGL has done and what it has become.
“The Croatian Bank for Reconstruction and Development is a tool of the government and its primary purpose is to encourage projects like this one. This is an investment in high technologies, knowledge, production and digitisation, which achieves global competitiveness. JGL makes the contribution to Croatia that we want to have. We’re proud of you and the state is here so that projects like INTEGRA can happen and work to make Croatia better,” said the Prime Minister at the occasion.
A quick look at INTEGRA in numbers:
Investment value: 53 million euros
Project duration: Three years
The growth of sterile production capacity – 60 percent (40 million products)
The total area of the new pharmaceutical production: 3250 m 2
The new pilot plant: 750 m 2
New laboratories and offices for research, development and quality control: 2450 m 2
The new Kukuljanovo logistics and distribution centre: 20,000 m2
The capacity of the Kukuljanovo logistics and distribution centre: 17,500 pallets
